Mexico Secures Historic Pharmaceutical Investment to Boost Health Sovereignty
August 7, 2025 Hour: 7:20 pm
Mexican President Claudia Sheinbaum Pardo announced a landmark investment of over 12 billion pesos (approx. US $641 million) from four multinational pharmaceutical companies and one Mexican firm. The initiative is part of her administration’s “Plan México, viento en popa”, aimed at strengthening domestic drug production, promoting health sovereignty, and generating thousands of jobs.
Investment Breakdown by Company
| Company | Investment (MXN) | Key Project |
|---|---|---|
| Boehringer Ingelheim | $3.5 billion | Transform Xochimilco plant into world’s largest tablet producer (5B units/year) |
| Laboratorios Carnot | $3.5 billion | Build new biopharma plant in Hidalgo, creating 600 direct jobs |
| Bayer México | $3 billion | Expand operations in Orizaba, Lerma, and Tlaxcala with sustainable tech |
| AstraZeneca | $2+ billion | Invest in clinical research and expand facilities in the State of Mexico |
Strategic Impact
- 3,000+ direct specialized jobs
- 20,000+ indirect jobs
- Export capacity to over 40 countries
- Strengthening of innovation hubs in Morelia and Villa de Tezontepec
- Enhanced regulatory efficiency via COFEPRIS, boosting investor confidence
President Sheinbaum emphasized that the investment reflects growing trust in Mexico’s regulatory and industrial environment. The Secretary of Health, David Kershenobich, called it a “major transformation,” positioning Mexico as a regional leader in pharmaceutical innovation and manufacturing.
Author: OSG
Source: teleSURtv
